ANIX ANIXA BIOSCIENCES INC revenue, earnings and financials
For the quarter ended July 31, 2026, ANIXA BIOSCIENCES INC reported revenue of n/a, net income of −$2.61M and diluted EPS of −$0.08; for the fiscal year ended October 2025 revenue was n/a.
ANIX annual revenue and earnings
- Fiscal year ended Oct 2025: revenue n/a, gross profit n/a, operating income −$11.7M, net income −$10.9M (margin n/a), EPS −$0.34
- Fiscal year ended Oct 2024: revenue $210K, gross profit n/a, operating income −$13.8M, net income −$12.6M (margin -5978.1%), EPS −$0.39
- Fiscal year ended Oct 2023: revenue $210K, gross profit n/a, operating income −$11.0M, net income −$9.81M (margin -4671.9%), EPS −$0.32
- Fiscal year ended Oct 2022: revenue n/a, gross profit n/a, operating income −$13.9M, net income −$13.6M (margin n/a), EPS $0.45
- Fiscal year ended Oct 2021: revenue $512K, gross profit n/a, operating income −$13.1M, net income −$13.0M (margin -2530.1%), EPS −$0.45
ANIX quarterly revenue and earnings
- Quarter ended Jul 31, 2026: revenue n/a, net income −$2.61M, EPS −$0.08
- Quarter ended Apr 30, 2026: revenue n/a, net income −$2.52M, EPS −$0.07
- Quarter ended Jan 31, 2026: revenue n/a, net income −$2.57M, EPS −$0.08
- Quarter ended Oct 31, 2025 (from the annual report): revenue n/a, net income −$2.70M, EPS −$0.08
- Quarter ended Jul 31, 2025: revenue n/a, net income −$2.26M, EPS −$0.07
- Quarter ended Apr 30, 2025: revenue n/a, net income −$2.79M, EPS −$0.09
- Quarter ended Jan 31, 2025: revenue n/a, net income −$3.18M, EPS −$0.10
- Quarter ended Oct 31, 2024 (from the annual report): revenue n/a, net income −$2.88M, EPS −$0.09
- Quarter ended Jul 31, 2024: revenue n/a, net income −$3.28M, EPS −$0.10
- Quarter ended Apr 30, 2024: revenue n/a, net income −$3.14M, EPS −$0.10
- Quarter ended Jan 31, 2024: revenue n/a, net income −$3.26M, EPS −$0.10
- Quarter ended Oct 31, 2023 (from the annual report): revenue n/a, net income −$2.69M, EPS −$0.25
- Quarter ended Jul 31, 2023: revenue n/a, net income −$2.51M, EPS −$0.08
- Quarter ended Apr 30, 2023: revenue $210K, net income −$2.29M, EPS −$0.07
- Quarter ended Jan 31, 2023: revenue n/a, net income −$2.32M, EPS $0.08
- Quarter ended Oct 31, 2022 (from the annual report): revenue n/a, net income −$3.48M, EPS n/a
- Quarter ended Jul 31, 2022: revenue n/a, net income −$2.75M, EPS −$0.09
- Quarter ended Apr 30, 2022: revenue n/a, net income −$3.54M, EPS n/a
- Quarter ended Jan 31, 2022: revenue $513K, net income −$3.83M, EPS −$0.13
- Quarter ended Jul 31, 2021: revenue n/a, net income −$4.33M, EPS −$0.14
ANIX cash flow, buybacks and dividends
- Fiscal year ended Oct 2025: operating cash flow −$7.17M, share buybacks n/a
- Fiscal year ended Oct 2024: operating cash flow −$7.34M, share buybacks $6.00K
- Fiscal year ended Oct 2023: operating cash flow −$6.21M, share buybacks n/a
- Fiscal year ended Oct 2022: operating cash flow −$6.49M, share buybacks n/a
- Fiscal year ended Oct 2021: operating cash flow −$4.94M, share buybacks n/a
ANIX balance sheet
- Jul 31, 2026: cash $1.40M, total assets $15.1M, total liabilities $1.87M, shareholders' equity $14.5M
- Apr 30, 2026: cash $1.48M, total assets $14.9M, total liabilities $1.64M, shareholders' equity $14.5M
- Jan 31, 2026: cash $1.55M, total assets $15.2M, total liabilities $1.39M, shareholders' equity $15.1M
- Oct 31, 2025: cash $1.24M, total assets $16.1M, total liabilities $2.13M, shareholders' equity $15.2M
- Jul 31, 2025: cash $1.50M, total assets $17.7M, total liabilities $2.24M, shareholders' equity $16.6M
- Apr 30, 2025: cash $1.91M, total assets $17.0M, total liabilities $2.07M, shareholders' equity $16.1M
- Jan 31, 2025: cash $1.05M, total assets $18.9M, total liabilities $2.19M, shareholders' equity $17.9M
- Oct 31, 2024: cash $1.27M, total assets $21.6M, total liabilities $2.70M, shareholders' equity $20.0M
Is ANIX profitable?
No. ANIXA BIOSCIENCES INC lost $10.4M over the last four quarters.
What is ANIX's EPS?
Diluted earnings per share over the last four quarters were −$0.31; −$0.08 in the latest quarter.